ReviveMed uses AI to gather large-scale data on metabolites — molecules like lipids, cholesterol, and sugar — to match patients with therapeutics.
MIT spinout ReviveMed uses AI and large-scale metabolomic data to analyze how treatments work and identify which patients may benefit most. By measuring metabolites—molecules like lipids, cholesterol, and sugar—the company aims to uncover why some patients respond to therapies while others do not. ReviveMed collaborates with hospitals to study metabolic changes in diseases and is making its generative models available to researchers to accelerate understanding of metabolites' role in various conditions. The company's goal is to create metabolic foundation models to help researchers and pharmaceutical companies understand how diseases and treatments affect patients' metabolites.
